Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD, MAFLD, or Both
We read with great interest the recently reported work regarding clinical profiles for metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic fatty liver disease (NAFLD) by Younossi 1. Metabolic dysfunction-associated fatty liver disease (MAFLD) and MASLD were introduced as new terminologies to address the limitations associated with NAFLD 2,3. MASLD encompasses patients with at least one of five cardiometabolic risk factors and captures more lean patients than MAFLD. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 28, 2024 Category: Gastroenterology Authors: Xiao-Dong Zhou, Amedeo Lonardo, Calvin Q. Pan, Michael D. Shapiro, Ming-Hua Zheng, WMU MAFLD Clinical Research Working Group Tags: Letter to the Editor Source Type: research

Response to letter entitled: Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 28, 2024 Category: Cancer & Oncology Authors: James A. Thomas, Bradley J. Kendall, Graeme A. Macdonald, Aaron P. Thrift Source Type: research

A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials
ConclusionWe summarised the landscape of current clinical trials and suggested the directions for future NAFLD therapy to assist internal medicine specialists in treating the whole clinical spectrum of this highly prevalent liver disease. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research

GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Curr Pharm Des. 2024;30(2):100-114. doi: 10.2174/0113816128283153231226103218.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) has recently emerged as a global public health concern. Currently, the cornerstone of NAFLD treatment is lifestyle modification and, if necessary, weight loss. However, compliance is a challenge, and this approach alone may not be sufficient to halt and treat the more serious disease development, so medication is urgently needed. Nevertheless, no medicines are approved to treat NAFLD. Glucagon-like peptide-1 (GLP-1) is an enteropeptide hormone that inhibits glucagon synthesis, promotes insulin sec...
Source: Current Pharmaceutical Design - March 27, 2024 Category: Drugs & Pharmacology Authors: Haoran Jiang Linquan Zang Source Type: research

Trimethylamine-N-oxide, a New Risk Factor for Non-alcoholic Fatty Liver Disease Changes the Expression of miRNA-34a, and miRNA-122 in the Fatty Liver Cell Model
This study investigated the expression of miRNA-34a, miRNA-122, and miRNA-192 in the fatty liver cell model treated with different concentrations of TMAO. A fatty liver cell model was developed by exposing HepG2 cells to a mixture of palmitate and oleate in a ratio of 1:2 at a final concentration of 1200 μM for 24 h. The confirmed fatty liver cells were treated with 37.5, 75, 150, and 300 μM of TMAO for 24 h. RT-qPCR was used to quantify the expression of microRNAs in a cellular model. The cellular expression of all microRNAs was significantly higher in treated fatty liver cells compared to normal HepG2 cells (P < 0.0...
Source: Biochemical Genetics - March 27, 2024 Category: Genetics & Stem Cells Authors: Zhila Bahramirad Mohammad Raman Moloudi Mohammad Moradzad Alina Abdollahi Zakaria Vahabzadeh Source Type: research